{
  "source": "PA-Notification-Bimzelx.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1437-3\nProgram Prior Authorization/Notification\nMedication Bimzelx® (bimekizumab-bkzx)\nP&T Approval Date 1/2025\nEffective Date 4/1/2025\n1. Background:\nBimzelx (bimekizumab-bkzx) is a humanized interleukin-17A and F antagonist indicated for\nthe treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic\ntherapy or phototherapy, adults with active psoriatic arthritis, adults with active non-\nradiographic axial spondyloarthritis with objective signs of inflammation, adults with active\nankylosing spondylitis, and adults with moderate to severe hidradenitis suppurativa.\n2. Coverage Criteriaa:\nA. Plaque Psoriasis (PsO)\n1. Initial Authorization\na. Bimzelx will be approved based on both of the following criteria:\n(1) Diagnosis of moderate to severe plaque psoriasis\n-AND-\n(2) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara\n(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx\n(secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya\n(tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Bimzelx will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Bimzelx therapy\n-AND-\n(2) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara\n© 2025 UnitedHealthcare Services, Inc.\n1\n(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx\n(secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya\n(tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (a",
    "nkizumab), Tremfya (guselkumab), Cosentyx\n(secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya\n(tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nB. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Bimzelx will be approved based on both of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), Stelara (ustekinumab), Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Bimzelx will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Bimzelx therapy\n-AND-\n(2) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), Stelara (ustekinumab), Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nC. Ankylosing Spondylitis (AS)\n1. Initial Authorization\na. Bimzelx will be approved based on both of the following criteria:\n(1) Diagnosis of active ankylosing spondylitis\n© 2025 UnitedHealthcare Services, Inc.\n2\n-AND-\n(2) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Bimzelx will be appro",
    "limumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Bimzelx will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Bimzelx therapy\n-AND-\n(2) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nD. Non-radiographic Axial Spondyloarthritis (nr-axSpA)\n1. Initial Authorization\na. Bimzelx will be approved based on both of the following criteria:\n(1) Diagnosis of non-radiographic axial spondyloarthritis\n-AND-\n(2) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Bimzelx will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Bimzelx therapy\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n3\n(2) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nE. Hidradenitis Suppurativa (HS)\n1. Initial Authorization\na. Bimzelx will be approved based on both of the following criteria:\n(1) Diagnosis of moderate to severe hidradenitis suppurativa\n-AND-\n(2) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Cosentyx\n(secukinumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia\n(abata",
    "not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Cosentyx\n(secukinumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia\n(abatacept), Simponi (golimumab), Rinvoq (upadacitinib), Xeljanz\n(tofacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Bimzelx will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Bimzelx therapy.\n-AND-\n(2) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Cosentyx\n(secukinumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia\n(abatacept), Simponi (golimumab), Rinvoq (upadacitinib), Xeljanz\n(tofacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\n© 2025 UnitedHealthcare Services, Inc.\n4\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits and/or step therapy may be in place.\n4. Reference:\n1. Bimzelx [package insert]. Smyrna, GA: UCB, Inc.; November 2024\nProgram Prior Authorization/Notification - Bimzelx (bimekizumab-bkzx)\nChange Control\n4/2024 New program\n10/2024 Removed notation of exclusion. Added coverage criteria for PsA, AS,\nand nr-axSpA. Updated background and reference.\n1/2025 Added criteria for hidradenitis suppurativa. Updated background and\nreference.\n© 2025 UnitedHealthcare Services, Inc.\n5"
  ]
}